• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Monday

    1/9/23 11:20:01 AM ET
    $ARVN
    $CERS
    $CIO
    $CUTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology
    Get the next $ARVN alert in real time by email

    Companies That Fell Through 52-Week Lows Monday

    During Monday's morning trading, 14 companies set new 52-week lows.

    Things to Consider About Today's 52-Week Lows:

    • L3Harris Technologies (NYSE:LHX) was the biggest company on a market cap basis to set a new 52-week low.
    • The smallest company by market cap to hit a new 52-week low was Nabriva Therapeutics (NASDAQ:NBRV).
    • Cutera (NASDAQ:CUTR) shares traded down 23.86% to reach its 52-week low, making it the biggest loser.
    • Nabriva Therapeutics (NASDAQ:NBRV)'s stock made the biggest reversal, trading up 0.77% shortly after dropping to a new 52-week low.

    Here is a list of stocks that set new 52-week lows on Monday:

    • L3Harris Technologies (NYSE:LHX) stock hit a new 52-week low of $200.33. The stock was down 1.31% on the session.
    • Arvinas (NASDAQ:ARVN) stock dropped to a yearly low on Monday of $27.00. Shares traded down 12.8%.
    • Cutera (NASDAQ:CUTR) shares hit a yearly low of $29.49. The stock was down 23.86% on the session.
    • Cerus (NASDAQ:CERS) shares set a new 52-week low of $3.06. The stock traded down 17.99%.
    • PMV Pharma (NASDAQ:PMVP) shares hit a yearly low of $8.08. The stock was down 3.23% on the session.
    • City Office REIT (NYSE:CIO) stock set a new 52-week low of $8.03 on Monday, moving down 1.72%.
    • PIMCO California (NYSE:PCQ) shares reached a new 52-week low of $12.20 on Monday morning, moving down 1.48%.
    • DLH Hldgs (NASDAQ:DLHC) stock hit a new 52-week low of $10.80. The stock was down 9.24% on the session.
    • Peak Bio (NASDAQ:PKBO) shares set a new yearly low of $2.84 this morning. The stock was down 11.93% on the session.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ARVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARVN
    $CERS
    $CIO
    $CUTR

    CompanyDatePrice TargetRatingAnalyst
    Arvinas Inc.
    $ARVN
    1/6/2026$15.00Neutral → Buy
    Citigroup
    L3Harris Technologies Inc.
    $LHX
    12/16/2025$367.00Equal-Weight → Overweight
    Morgan Stanley
    L3Harris Technologies Inc.
    $LHX
    12/12/2025$331.00Buy
    Citigroup
    L3Harris Technologies Inc.
    $LHX
    11/18/2025$290.00Neutral
    BNP Paribas Exane
    Arvinas Inc.
    $ARVN
    10/15/2025$6.00Neutral → Sell
    Goldman
    Arvinas Inc.
    $ARVN
    9/24/2025$10.00Buy → Neutral
    BofA Securities
    Arvinas Inc.
    $ARVN
    9/17/2025$16.00Overweight
    Barclays
    Arvinas Inc.
    $ARVN
    6/2/2025$9.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $ARVN
    $CERS
    $CIO
    $CUTR
    SEC Filings

    View All

    SEC Form S-8 filed by PMV Pharmaceuticals Inc.

    S-8 - PMV Pharmaceuticals, Inc. (0001699382) (Filer)

    3/6/26 9:23:25 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)

    3/6/26 8:24:33 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by PMV Pharmaceuticals Inc.

    10-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)

    3/6/26 8:01:20 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $CERS
    $CIO
    $CUTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Mink Brook Asset Management Llc bought $44,264 worth of shares (8,048 units at $5.50) (SEC Form 4)

    4 - DLH Holdings Corp. (0000785557) (Issuer)

    2/20/26 4:31:07 PM ET
    $DLHC
    Professional Services
    Consumer Discretionary

    Large owner Mink Brook Asset Management Llc bought $135,844 worth of shares (24,699 units at $5.50) (SEC Form 4)

    4 - DLH Holdings Corp. (0000785557) (Issuer)

    2/18/26 5:23:56 PM ET
    $DLHC
    Professional Services
    Consumer Discretionary

    Large owner Mink Brook Asset Management Llc bought $76,428 worth of shares (13,896 units at $5.50) (SEC Form 4)

    4 - DLH Holdings Corp. (0000785557) (Issuer)

    2/13/26 5:01:22 PM ET
    $DLHC
    Professional Services
    Consumer Discretionary

    $ARVN
    $CERS
    $CIO
    $CUTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

    Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutationRezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancerNew England Journal of Medicine published first-in-human rezatapopt data showing selective reactivation of mutant p53 in advanced solid tumorsRezatapopt New Drug Application submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027Cash, cash equivalents, and marketable securities of $112.9 million as of December 31, 2025 providing

    3/6/26 8:00:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intuitive Machines Selected by L3Harris to Support SDA Proliferated Warfighter Space Architecture Tranche 3 Tracking Layer

    HOUSTON, March 03, 2026 (GLOBE NEWSWIRE) -- Intuitive Machines, Inc. (NASDAQ:LUNR) ("Intuitive Machines" or the "Company"), a leading space technology, infrastructure, and services company, today announced Lanteris Space Systems, a wholly owned subsidiary of Intuitive Machines, was selected by L3Harris Technologies (NYSE:LHX) to support the development and production of spacecraft platforms for the Space Development Agency ("SDA") Tranche 3 Tracking Layer of the Proliferated Warfighter Space Architecture. Under this selection, Intuitive Machines will design, build and deliver 18 advanced spacecraft platforms to help enable the next generation of space-based missile tracking capabilities.

    3/3/26 8:30:00 AM ET
    $LHX
    $LUNR
    Industrial Machinery/Components
    Industrials

    PIMCO Closed-End Funds Declare Monthly Common Share Distributions

    NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- The Boards of Trustees/Directors of the PIMCO closed-end funds below (each, a "Fund" and, collectively, the "Funds") have declared a monthly distribution for each Fund's common shares as summarized below. For the following Funds, the distributions are payable on April 1, 2026 to shareholders of record on March 12, 2026, with an ex-dividend date of March 12, 2026:   Monthly Distribution  Per ShareFundNYSE SymbolAmountChange From Previous MonthPercentageChange From Previous MonthPIMCO Corporate & Income Strategy Fund(NYSE:PCN)$0.112500--PIMCO Corporate & Income Opportunity Fund(NYSE:PTY)$0.118800--PIMCO Global StocksPLUS® & Income Fund(NYSE:PGP)$

    3/2/26 4:42:58 PM ET
    $PAXS
    $PCM
    $PCN
    Investment Managers
    Finance
    Trusts Except Educational Religious and Charitable
    Finance/Investors Services

    $ARVN
    $CERS
    $CIO
    $CUTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Arvinas upgraded by Citigroup with a new price target

    Citigroup upgraded Arvinas from Neutral to Buy and set a new price target of $15.00

    1/6/26 8:21:48 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    L3Harris upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded L3Harris from Equal-Weight to Overweight and set a new price target of $367.00

    12/16/25 8:39:52 AM ET
    $LHX
    Industrial Machinery/Components
    Industrials

    Citigroup initiated coverage on L3Harris with a new price target

    Citigroup initiated coverage of L3Harris with a rating of Buy and set a new price target of $331.00

    12/12/25 8:51:27 AM ET
    $LHX
    Industrial Machinery/Components
    Industrials

    $ARVN
    $CERS
    $CIO
    $CUTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Benjamin Richard J was granted 264,000 shares, increasing direct ownership by 38% to 949,775 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    3/4/26 8:37:44 PM ET
    $CERS
    EDP Services
    Technology

    Chief Financial Officer Green Kevin Dennis was granted 300,000 shares, increasing direct ownership by 34% to 1,187,262 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    3/4/26 8:36:24 PM ET
    $CERS
    EDP Services
    Technology

    President and CEO Greenman William Mariner was granted 1,200,000 shares, increasing direct ownership by 29% to 5,331,167 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    3/4/26 8:33:35 PM ET
    $CERS
    EDP Services
    Technology

    $ARVN
    $CERS
    $CIO
    $CUTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PMV Pharmaceuticals Inc.

    SC 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    12/12/24 12:29:41 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by City Office REIT Inc.

    SC 13G/A - City Office REIT, Inc. (0001593222) (Subject)

    11/14/24 4:05:11 PM ET
    $CIO
    Real Estate Investment Trusts
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

    SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

    11/14/24 1:22:38 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $CERS
    $CIO
    $CUTR
    Financials

    Live finance-specific insights

    View All

    Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

    2025 Total Revenue of $233.8 million, up 16% from 2024; 2025 Product Revenue of $206.1 million, up 14% from 2024 Strengthened Financial Foundation Through Strong Commercial Execution and Disciplined Operational Management Cerus Corporation (NASDAQ:CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. "Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components," said William "Obi" Greenman, Cerus' pres

    3/2/26 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    – Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – – ARV-102 (LRRK2) Phase 1 clinical data in patients with Parkinson's disease accepted for oral presentation at AP/PD Conference in March 2026 – – Clinical data from ARV-806 (KRAS G12D) and ARV-393 (BCL6) on track for presentations in 2026 – – Phase 1 trial in healthy volunteers initiated with polyQ-AR degrader ARV-027; first immuno-oncology PROTAC HPK1 degrader, ARV-6723, on track to initiate Phase 1 trial in mid-2026 – – Randy Teel, Ph.D., appointed President, Chief Executive Officer, and

    2/24/26 7:00:00 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026

    Cerus Corporation (NASDAQ:CERS) announced today its fourth quarter and full-year 2025 financial results will be released on Monday, March 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay will

    2/17/26 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    $ARVN
    $CERS
    $CIO
    $CUTR
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Oksenholt Capital Slams City Office REIT's "Lowball" Elliott Capital Offer, Calls for New Leadership and Strategic Restructuring

      Oksenholt Capital Management LLC ("Oksenholt Capital") today announced that its Chief Executive Officer, Jon Oksenholt, has sent a formal letter to the Chairman of the Board of City Office REIT, Inc. (NYSE:CIO), outlining serious concerns about the company's leadership, performance, and opposition to the proposed merger with affiliates of Elliott Capital. The letter identified several issues related to City Office REIT, Inc.'s ("CIO") current management and voiced opposition to the pending proposed acquisition/merger with affiliates of Elliott Capital. Affiliates of Oksenholt Capital Management LLC have Acquired Several Hundred Thousand Shares of City Office REIT, Inc., Comprising

    10/7/25 6:00:00 PM ET
    $CIO
    Real Estate Investment Trusts
    Real Estate

    Global Threat Surge Leads to $2.7T Defense Spending Boom and Institutional Rush

    Equity Insider News Commentary Issued on behalf of VisionWave Holdings, Inc. VANCOUVER, BC, Sept. 26, 2025 /PRNewswire/ -- Global military spending hit a record $2.7 trillion in 2024, marking a 9.4% surge that represents the steepest year-over-year increase in at least three decades as nations respond to "intensifying wars and rising geopolitical tensions worldwide," according to UN report[1]. NATO's updated defense expenditure data released in August confirms all 32 allies are expected to meet the 2% GDP spending target this year, while the alliance's commitment to reach 5% of GDP by 2035 creates unprecedented demand for advanced military technologies and platforms[2]. This defense spending

    9/26/25 10:30:00 AM ET
    $GD
    $LHX
    $LMT
    Marine Transportation
    Industrials
    Industrial Machinery/Components
    Military/Government/Technical